Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Randomized, Multicenter, Parallel-Group Efficacy and Safety Study of Tacrolimus Immunosuppressive Therapy After Kidney Transplantation

NCT00717379 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00717379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00717379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Randomized, Multicenter, Parallel-Group Efficacy and Safety Study of Tacrolimus Immunosuppressive Therapy After Kidney Transplantation
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2007
Completion date
October 31, 2008
Enrollment
50 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

kidney failure, chronic, kidney transplantation, renal insufficiency, chronic